⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23108145 | 0.89 | ESR2 (0.35) | — | |
| SCHEMBL23108146 | 0.89 | ESR2 (0.35) | — | |
| SCHEMBL679892 | 0.89 | KMO (0.37) | — | |
| Hydrochloric Acid SCHEMBL3646919 | 0.83 | HRH4 (0.40) | — | |
| SCHEMBL23108065 | 0.74 | OPRM1 (0.41) | — | |
| SCHEMBL9342833 | 0.66 | CHRNA7 (0.43) | — | |
| SCHEMBL7964249 | 0.66 | TSHR (0.50) | — | |
| SCHEMBL8215186 | 0.63 | PARP1 (0.34) | — | |
| SCHEMBL12588901 | 0.61 | KDM4E (0.37) | — | |
| SCHEMBL3708961 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025016323-A1 | PROTEIN ARGINASE METHYLTRANSFERASE-5 INHIBITOR AND MEDICAL USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2025-01-23 | — | — | WO | disclosed |
| WO-2024256438-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA CROP PROTECTION AG (CH) | 2024-12-19 | — | — | WO | disclosed |
| WO-2023001061-A1 | CDK7 SELECTIVE INHIBITORS AS ANTICANCER AGENTS | JINGRUI BIOPHARMA CO., LTD. (CN) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023001061-A1 | CDK7 SELECTIVE INHIBITORS AS ANTICANCER AGENTS | JINGRUI BIOPHARMA CO., LTD. (CN) | 2023-01-26 | — | — | WO | disclosed |
| EP-4101297-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Pharmaceuticals, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220289751-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-09-15 | — | — | US | disclosed |
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2022-04-12 | — | — | US | disclosed |
| US-20220016086-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | EyePoint Pharmaceuticals, Inc. | 2022-01-20 | — | — | US | disclosed |
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2020-11-19 | — | — | US | disclosed |
| EP-3323815-B1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS LLC (US) | 2020-10-07 | — | — | EP | disclosed |
| US-8569348-B2 | Compounds, compositions, and methods for preventing metastasis of cancer cells | AERPIO THERAPEUTICS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2592072-A2 | Human protein tyrosine phosphatase inhibitors and their use | Warner Chilcott Company, LLC (PR) | 2013-05-15 | — | — | EP | disclosed |
| US-20120128625-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EyePoint, Inc. | 2012-05-24 | — | — | US | disclosed |
| US-20120129847-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | EyePoint Pharmaceuticals, Inc. | 2012-05-24 | — | — | US | disclosed |
| EP-1852428-B1 | 4-CYCLOPROPYL-1,2,3-THIADIAZOLE COMPOUND, AGROHORTICULTURAL PLANT DISEASE CONTROLLING AGENT AND METHOD OF USING THE SAME | NIHON NOHYAKU CO LTD (JP) | 2012-05-16 | — | — | EP | disclosed |
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2011-11-03 | — | — | US | disclosed |
| US-7622593-B2 | 4-{2-[2-(tert-Butoxycarbonyl)-3-phenylpropanamido]-2-(4-ethylthiazol-2-yl)ethyl}phenylsulfamic acid; anticarcinogenic, antitumor, antidiabrtic agent; angiogenesis inhibitor; sarcoid, syphilis, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis | THE PROCTER & GAMBLE COMPANY (US) | 2009-11-24 | — | — | US | disclosed |
| EP-2041102-A2 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | The Procter & Gamble Company (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080108631-A1 | 4-{2-[2-(tert-Butoxycarbonyl)-3-phenylpropanamido]-2-(4-ethylthiazol-2-yl)ethyl}phenylsulfamic acid; anticarcinogenic, antitumor, antidiabrtic agent; angiogenesis inhibitor; sarcoid, syphilis, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis | THE PROCTER & GAMBLE COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| WO-2008002569-A2 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |